Market Overview

Novo Nordisk Announces Positive Phase 2 Trial Results, Shares Spike Higher


Shares of Novo Nordisk A/S (NYSE: NVO) were trading higher by more than 4 percent Friday morning after the company announced positive results from a phase 2 FDA trial.

Novo Nordisk announced that it "has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks."

Shares traded recently at $47.16, up 4.4 percent.

Posted-In: Diabities Novo Nordisk OG217SC Phase 2News Health Care FDA General


Related Articles (NVO)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Cocoa Little Higher, Coffee Steady

Swift Transportation: Citi Discusses 'Tactical Outlook For Truck Carriers, OEMs And Suppliers'